CPT® Code 79403

Radiopharmaceutical therapy involving radiolabeled monoclonal antibodies (mAbs, moAbs) by intravenous (IV) infusion is a specialized treatment that utilizes targeted therapy to treat certain types of cancer. This procedure begins with the establishment of an intravenous access line, which is essential for the administration of the therapeutic agent. The radiolabeled monoclonal antibody is a type of protein that is engineered to specifically bind to a particular protein antigen found on the surface of cancer cells. Once administered, the radiolabeled antibody circulates through the bloodstream and seeks out cells that express the target antigen, allowing for precise delivery of radiation directly to the cancerous cells. This targeted approach minimizes damage to surrounding healthy tissues and enhances the effectiveness of the treatment. An example of this therapy is Ibritumomab tiuxetan (Zevalin), which specifically targets the CD20 antigen present on B-cell lymphocytes, making it a valuable option for patients with non-Hodgkin lymphoma. This innovative treatment modality is often referred to as radioimmunotherapy, highlighting its dual role in both immunotherapy and radiation therapy.